Shape‑memory polymer to seal the false lumen and prevent aortic enlargement
Official title: False Lumen Treatment for Prevention of Aortic Growth Using Shape Memory Polymer - First-in-Human Study
Run by Shape Memory Medical, Inc. · NCT06550986 · Data updated 2026-11-12
This trial will try a shape‑memory polymer implant to seal the false lumen and stop aortic growth in adults with type B dissection or treated type A dissection who need false lumen repair.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | Shape Memory Medical, Inc. Industry-sponsored |
| Locations | 2 sites (Auckland and 1 other locations) |
| Status | Recruiting |
| Started | February 24, 2026 |
| Main results expected | February 15, 2027 |
| Study ends | February 15, 2029 |
| Registry record updated | March 23, 2026 |
| Trial ID | NCT06550986 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults (≥18) with a type B dissection or a previously treated primary entry who now have a persistent false lumen amenable to endovascular embolization and with vascular anatomy suitable for device delivery.
✕Probably not a fit
Patients in the hyperacute/acute phase (<15 days), those with untreated proximal tears, prior false lumen treatment, unsuitable vascular anatomy, or who cannot provide informed consent are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This first‑in‑human interventional trial tests a False Lumen Embolization System (IMPEDE‑FX RapidFill) made from a shape‑memory polymer, delivered endovascularly into the false lumen to reduce blood flow. Participants include adults with type B dissection without prior primary entry treatment or patients with a previously treated primary entry who now have a persistent false lumen requiring treatment. The procedure places and expands the polymer device in the false lumen to promote occlusion while the study tracks procedural feasibility, device behavior, safety events, and imaging changes in false lumen perfusion and aortic size over follow‑up. Patients with unsuitable anatomy, untreated proximal tears, recent acute dissections, or prior false lumen treatment are excluded to reduce procedural risk.
Why it matters
Potential benefit: If successful, the device could reduce false lumen perfusion, slow or stop aortic enlargement, and lower the need for further open or endovascular surgeries.
How similar studies have gone: This is a first‑in‑human application of this shape‑memory polymer for aortic false lumen occlusion; while other embolic materials have been used in peripheral and neurovascular settings, evidence for false lumen aortic occlusion is limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * ≥18 years of age. * A candidate for false lumen (FL) embolization with a type B dissection, and no prior primary entry tear/TL treatment, OR * A candidate for FL embolization with a type B or type A dissection, in whom the primary entry tear/TL was treated in a previous procedure, and is now presenting with a FL requiring treatment. Exclusion Criteria: * An inability to provide informed consent. * Enrolled in another clinical study other than a registry. * Hyperacute or acute aortic dissection (\<15 days from symptom onset). * Untreated or uncovered primary entry/reentry tear proximal to left subclavian artery (before FL treatment with the investigational product). * Vascular disease, aortic rupture, and/or anatomy and/or dissection membrane condition that precludes the safe access and positioning of an introducer sheath and delivery (and expansion) of the investigational product into the FL. * Prior treatment of the FL. * Planned use of investigational devices to treat the primary entry tear and/or TL. * Absence of/inability to create a reentry tear/fenestration adequately positioned and large enough to allow introducer sheath access into the FL. * Planned use of FL embolic devices other than the investigational product. * Prior abdominal aortic aneurysm (AAA) treatment. * Planned concomitant major surgery (e.g., gastrointestinal surgery). * Diagnosed or suspected congenital degenerative connective tissue disease (e.g., Marfan's or Ehler-Danlos syndrome). * Coagulopathy or uncontrolled bleeding disorder. * Serum creatinine level \>220 µmol/L (within 90 days prior to the procedure). * Cerebrovascular accident within 90 days prior to the procedure. * Myocardial infarction and/or major heart surgery within 90 days prior to the procedure. * Atrial fibrillation that is not well rate controlled. * Unable or unwilling to comply with study follow-up requirements. * Life expectancy of \<2 years postprocedure. * Known hypersensitivity or contraindication to platinum, iridium, or polyurethane. * A condition that inhibits radiographic visualization during the study procedure and planned follow-up imaging. * History of allergy to contrast medium that cannot be managed medically. * Uncontrolled comorbid medical condition, including mental health issues, that, in the opinion of the investigator, would adversely affect participation in the study. * Participant is planning to become pregnant or is currently pregnant or lactating. For participants of child-bearing potential, based on a positive pregnancy test within 7 days prior to the procedure or refusal to use a medically accepted method of birth control for the duration of the study.
Where it's running
-
Auckland City Hospital
Auckland, New Zealand Recruiting -
Waikato Hospital
Hamilton, New Zealand Recruiting
Study contacts
- Study coordinator: Peter Miller, M.S.
- Email: p.miller@shapemem.com
- Phone: +1 408 649 5175
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Pregnancy-Related Aortic Dissection in China
This study looks at cases of aortic dissection that occur during pregnancy or shortly after, to understand outcomes for mothers and babies.
-
Ketorolac to improve outcomes and prognosis in Stanford Type A aortic dissection
This trial will test whether giving ketorolac around emergency surgery helps adults (18–65) with Stanford Type A aortic dissection recover better and have fewer complications over 90 days.
-
WeFlow-EndoPatch for Distal Aortic Tear Repair in Chronic Dissection
This study tests whether the WeFlow-EndoPatch Aortic Endovascular Patch can safely and effectively seal distal tears in chronic aortic dissection compared with standard treatment.
-
Aortic arch single-branch covered stent graft for treating aortic dissection
This trial tests a single-branch covered stent graft in adults with Stanford Type B aortic dissection who need revascularization of the left subclavian artery.
-
Multicenter study on acute type A aortic dissection
This study is trying to learn more about patients with acute type A aortic dissection by looking at their health details, surgeries, and recovery to see what affects their outcomes.
-
Using sivelestat to protect lung function after heart surgery
This study is testing if giving sivelestat to patients having emergency heart surgery can help protect their lungs and improve recovery by reducing serious complications.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.